Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma

May 08, 2019
PREVAIL
Bladder Cancer
Brian Myre, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

The purpose of this study is to assess the prevalence of pre-treatment tumor tissue PD-L1 expression in patients diagnosed with advanced urothelial carcinoma.

AstraZeneca

https://clinicaltrials.gov/ct2/show/NCT03788746

  • No prior systemic therapy for advanced UC
  • No platinum-based chemotherapy within last 12 months
  • No history of non-urothelial active malignancy that completed therapy within 2 years from study enrollment except: 1) resected in situ carcinoma or non-melanoma skin cancer, 2) early stage cancer treated without systemic therapy
     
5 years
Accepting Participants
Interventional
Kathy Seymour, BSN
630-646-6075
630-646-6110
630-646-6072